Prevalence of subclinical pulmonary tuberculosis in adults in community settings: an individual participant data meta-analysis.


Journal

The Lancet. Infectious diseases
ISSN: 1474-4457
Titre abrégé: Lancet Infect Dis
Pays: United States
ID NLM: 101130150

Informations de publication

Date de publication:
12 Mar 2024
Historique:
received: 05 11 2023
revised: 17 12 2023
accepted: 09 01 2024
medline: 16 3 2024
pubmed: 16 3 2024
entrez: 15 3 2024
Statut: aheadofprint

Résumé

Subclinical pulmonary tuberculosis, which presents without recognisable symptoms, is frequently detected in community screening. However, the disease category is poorly clinically defined. We explored the prevalence of subclinical pulmonary tuberculosis according to different case definitions. We did a one-stage individual participant data meta-analysis of nationally representative surveys that were conducted in countries with high incidence of tuberculosis between 2007 and 2020, that reported the prevalence of pulmonary tuberculosis based on chest x-ray and symptom screening in participants aged 15 years and older. Screening and diagnostic criteria were standardised across the surveys, and tuberculosis was defined by positive Mycobacterium tuberculosis sputum culture. We estimated proportions of subclinical tuberculosis for three case definitions: no persistent cough (ie, duration ≥2 weeks), no cough at all, and no symptoms (ie, absence of cough, fever, chest pain, night sweats, and weight loss), both unadjusted and adjusted for false-negative chest x-rays and uninterpretable culture results. We identified 34 surveys, of which 31 were eligible. Individual participant data were obtained and included for 12 surveys (620 682 participants) across eight countries in Africa and four in Asia. Data on 602 863 participants were analysed, of whom 1944 had tuberculosis. The unadjusted proportion of subclinical tuberculosis was 59·1% (n=1149/1944; 95% CI 55·8-62·3) for no persistent cough and 39·8% (773/1944; 36·6-43·0) for no cough of any duration. The adjusted proportions were 82·8% (95% CI 78·6-86·6) for no persistent cough and 62·5% (56·6-68·7) for no cough at all. In a subset of four surveys, the proportion of participants with tuberculosis but without any symptoms was 20·3% (n=111/547; 95% CI 15·5-25·1) before adjustment and 27·7% (95% CI 21·0-36·4) after adjustment. Tuberculosis without cough, irrespective of its duration, was more frequent among women (no persistent cough: adjusted odds ratio 0·79, 95% CI 0·63-0·97; no cough: adjusted odds ratio 0·76, 95% CI 0·62-0·93). Among participants with tuberculosis, 29·1% (95% CI 25·2-33·3) of those without persistent cough and 23·1% (18·8-27·4) of those without any cough had positive smear examinations. The majority of people in the community who have pulmonary tuberculosis do not report cough, a quarter report no tuberculosis-suggestive symptoms at all, and a quarter of those not reporting any cough have positive sputum smears, suggesting infectiousness. In high-incidence settings, subclinical tuberculosis could contribute considerably to the tuberculosis burden and to Mycobacterium tuberculosis transmission. Mr Willem Bakhuys Roozeboom Foundation.

Sections du résumé

BACKGROUND BACKGROUND
Subclinical pulmonary tuberculosis, which presents without recognisable symptoms, is frequently detected in community screening. However, the disease category is poorly clinically defined. We explored the prevalence of subclinical pulmonary tuberculosis according to different case definitions.
METHODS METHODS
We did a one-stage individual participant data meta-analysis of nationally representative surveys that were conducted in countries with high incidence of tuberculosis between 2007 and 2020, that reported the prevalence of pulmonary tuberculosis based on chest x-ray and symptom screening in participants aged 15 years and older. Screening and diagnostic criteria were standardised across the surveys, and tuberculosis was defined by positive Mycobacterium tuberculosis sputum culture. We estimated proportions of subclinical tuberculosis for three case definitions: no persistent cough (ie, duration ≥2 weeks), no cough at all, and no symptoms (ie, absence of cough, fever, chest pain, night sweats, and weight loss), both unadjusted and adjusted for false-negative chest x-rays and uninterpretable culture results.
FINDINGS RESULTS
We identified 34 surveys, of which 31 were eligible. Individual participant data were obtained and included for 12 surveys (620 682 participants) across eight countries in Africa and four in Asia. Data on 602 863 participants were analysed, of whom 1944 had tuberculosis. The unadjusted proportion of subclinical tuberculosis was 59·1% (n=1149/1944; 95% CI 55·8-62·3) for no persistent cough and 39·8% (773/1944; 36·6-43·0) for no cough of any duration. The adjusted proportions were 82·8% (95% CI 78·6-86·6) for no persistent cough and 62·5% (56·6-68·7) for no cough at all. In a subset of four surveys, the proportion of participants with tuberculosis but without any symptoms was 20·3% (n=111/547; 95% CI 15·5-25·1) before adjustment and 27·7% (95% CI 21·0-36·4) after adjustment. Tuberculosis without cough, irrespective of its duration, was more frequent among women (no persistent cough: adjusted odds ratio 0·79, 95% CI 0·63-0·97; no cough: adjusted odds ratio 0·76, 95% CI 0·62-0·93). Among participants with tuberculosis, 29·1% (95% CI 25·2-33·3) of those without persistent cough and 23·1% (18·8-27·4) of those without any cough had positive smear examinations.
INTERPRETATION CONCLUSIONS
The majority of people in the community who have pulmonary tuberculosis do not report cough, a quarter report no tuberculosis-suggestive symptoms at all, and a quarter of those not reporting any cough have positive sputum smears, suggesting infectiousness. In high-incidence settings, subclinical tuberculosis could contribute considerably to the tuberculosis burden and to Mycobacterium tuberculosis transmission.
FUNDING BACKGROUND
Mr Willem Bakhuys Roozeboom Foundation.

Identifiants

pubmed: 38490237
pii: S1473-3099(24)00011-2
doi: 10.1016/S1473-3099(24)00011-2
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Investigateurs

Jane Ruth Aceng (JR)
Ifedayo Adetifa (I)
Phonaly Chittamani (P)
Donekham Inthavong (D)
Farzanah Ismail (F)
Moses Joloba (M)
Simon Kasozi (S)
Harriet Kisembo (H)
Martie Van der Merwe (M)
Nkateko Mkhondo (N)
Joanita Nalunjogi (J)
Sakhone Sutepmani (S)

Informations de copyright

Copyright © 2024 World Health Organization. Published by Elsevier Ltd. All rights reserved. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests We declare no competing interests.

Auteurs

Logan Stuck (L)

Department of Global Health, Amsterdam University Medical Centers, Amsterdam, Netherlands; Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands.

Eveline Klinkenberg (E)

Department of Global Health, Amsterdam University Medical Centers, Amsterdam, Netherlands.

Nahid Abdelgadir Ali (N)

Global Fund Project Management Unit, International Health, Federal Ministry of Health, Khartoum, Sudan.

Egbal Ahmed Basheir Abukaraig (EA)

Research and Development Centre, Alfjr College for Science and Technology, Khartoum, Sudan.

Yaw Adusi-Poku (Y)

National Tuberculosis Control Programme, Ghana Health Service, Accra, Ghana.

Zeleke Alebachew Wagaw (Z)

Sustaining Technical and Analytical Resources, Accra, Ghana.

Razia Fatima (R)

Research Unit, Common Management Unit [TB, HIV/AIDS & Malaria], Islamabad, Pakistan.

Nathan Kapata (N)

Ministry of Health, Lusaka, Zambia; Zambia National Public Health Institute, Lusaka, Zambia.

Pascalina Kapata-Chanda (P)

Ministry of Health, Lusaka, Zambia.

Bruce Kirenga (B)

Makerere University Lung Institute & Division of Pulmonary Medicine, Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.

Llang B Maama-Maime (LB)

Ministry of Health National TB and Leprosy Programme, Maseru, Lesotho.

Sayoki G Mfinanga (SG)

National Institute for Medical Research, Muhimbili Research Centre, Dar es Salaam, Tanzania; University College London, London, UK; Alliance for Africa Health and Research (A4A), Dar es Salaam, Tanzania.

Sizulu Moyo (S)

Human Sciences Research Council, Cape Town, South Africa.

Lindiwe Mvusi (L)

Tuberculosis Programme, National Department of Health, Pretoria, South Africa.

Ndahafa Nandjebo (N)

National Tuberculosis and Leprosy Programme, Windhoek, Namibia.

Hai Viet Nguyen (HV)

Ministry of Health, Ha Noi, Viet Nam.

Hoa Binh Nguyen (HB)

National Lung Hospital, National Tuberculosis Control Programme, Ha Noi, Viet Nam.

Joshua Obasanya (J)

Nigeria Centre for Disease Control, Abuja, Nigeria.

Bashorun Adedapo Olufemi (B)

Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia.

Philip Patrobas Dashi (P)

WHO, Abuja, Nigeria.

Thato J Raleting Letsie (TJ)

Ministry of Health National TB and Leprosy Programme, Maseru, Lesotho.

Nunurai Ruswa (N)

Ministry of Health and Social Services, Windhoek, Namibia.

Elizeus Rutebemberwa (E)

Makerere University School of Public Health, Kampala, Uganda.

Mbazi Senkoro (M)

National Institute for Medical Research, Muhimbili Research Centre, Dar es Salaam, Tanzania.

Tieng Sivanna (T)

National Center for TB and Leprosy Control, Phnom Penh, Cambodia.

Huot Chan Yuda (HC)

National Center for TB and Leprosy Control, Phnom Penh, Cambodia.

Irwin Law (I)

Global Tuberculosis Programme, WHO, Geneva, Switzerland.

Ikushi Onozaki (I)

Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Tokyo, Japan.

Edine Tiemersma (E)

KNCV Tuberculosis Foundation, The Hague, Netherlands.

Frank Cobelens (F)

Department of Global Health, Amsterdam University Medical Centers, Amsterdam, Netherlands; Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands. Electronic address: f.cobelens@aighd.org.

Classifications MeSH